Global Digital Genome Market Size (2024 - 2029)

The digital genome market is experiencing significant growth, driven by technological advancements and the increasing adoption of personalized medicine. The COVID-19 pandemic has further accelerated demand for digital genome products, as it highlighted the importance of genomic sequencing in managing health crises. Despite challenges such as high capital costs and a shortage of skilled professionals, the market's expansion is supported by ongoing research and development activities. The integration of genomics-based artificial intelligence into healthcare workflows is also contributing to the market's growth trajectory.

Market Size of Global Digital Genome Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
digital genome market
Study Period 2019 - 2029
Market Size (2024) USD 30.68 Billion
Market Size (2029) USD 57.68 Billion
CAGR (2024 - 2029) 13.46 %
Fastest Growing Market Asia-Pacific
Largest Market North America

Major Players

rd-img

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Digital Genome Market Analysis

The Global Digital Genome Market size is estimated at USD 30.68 billion in 2024, and is expected to reach USD 57.68 billion by 2029, growing at a CAGR of 13.46% during the forecast period (2024-2029).

The COVID-19 pandemic is an unprecedented health concern and has significantly impacted the digital genome market worldwide. The pandemic has positively impacted the demand for digital genome software and products. For instance, as per a February 2022 published article titled, "Covid-19 and Artificial Intelligence: Genome sequencing, drug development, and vaccine discovery", the sequence of SARS- CoV-2 was identified with the help of AI and also aids in the prompt identification of variants of concern (VOC) as delta strains and Omicron. In addition, as per a May 2022 update by the Pan American Health Organization (PAHO), the COVID-19 Genomic Surveillance Regional Network was created in 2020 not only to strengthen the sequencing capacity in the participating laboratories but also for them to establish a routine SARS-CoV-2 genomic sequencing, as a strategy to increase the amount of genetic sequence data available to the global community, which is critical to support the development of diagnostic protocols, the information for vaccine development and to better understand the evolution and molecular epidemiology of the SARS-CoV-2. Moreover, with the introduction of vaccines and the upliftment of lockdown restrictions, the market is expected to increase the demand for digital genome products, thereby contributing to market growth.

The major factors fueling the market growth are the increasing technological advancements pertaining to the digital genome, growing adoption of personalized medicine, constantly evolving disease patterns as well as rising research and development activities about the digital genome.

The increasing technological advancement pertaining to the digital genome is proliferating market growth. For instance, in July 2021, GE Healthcare and SOPHiA GENETICS, a global healthcare data-sharing network, collaborated on advancing cancer care by developing genomic-based AI. The integration of genomics-based artificial intelligence into oncology workflow solutions would be a breakthrough for integrated cancer medicine and for future clinical research, which increasingly depends on the ability to select those patients most likely to respond to new therapies.

In addition, in April 2021, Genome Medical, a digital health company bringing genetics and genomics into everyday care, expanded its technology offering to augment the clinical services provided by its nationwide team of genetics specialists. Genome Medical will automate the collection of a patient's comprehensive family health history and incorporate the findings into an accurate and timely genetic risk assessment rough an exclusive licensing of Health Heritage, a family medical history, and genomic decision support application.

However, high capital expenditure and a lack of a skilled workforce are the factors hindering the market growth.

Digital Genome Industry Segmentation

As per the scope of the report, the digital genome is a comprehensive digital set of genetic material that occurs in a cell or an organism to gather information concerning chronic diseases and is utilized by experts to get a nearer look at genetic disorders. The market is segmented by product (Sequencing and Analyzer Instruments, DNA/RNA Analysis kits, Sequencing Chips, Sequencing and Analysis Software, Sample Preparation Instruments, and Other Products), Application (Clinical (Reproductive health, oncology, and others), Forensics, Drug discovery and development, and other applications), End-user (Hospitals, Diagnostic centers, and Forensic labs, Research Institutes, Other End Users), and Geography (North America, Europe, Asia Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Product
Sequencing and Analyzer Instruments
DNA/RNA Analysis Kits
Sequencing Chips
Sequencing and Analysis Software
Sample Preparation Instruments
By Application
Clinical
Reproductive Health
Oncology
Others
Forensics
Drug Discovery and Development
Other Applications
By End User
Hospitals
Diagnostic Centers and Forensic Labs
Research Institutes
Other End Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Global Digital Genome Market Size Summary

The digital genome market is poised for substantial growth, driven by technological advancements and the increasing adoption of personalized medicine. The market has experienced a positive impact from the COVID-19 pandemic, which highlighted the importance of genomic sequencing in understanding and combating the virus. This has led to a surge in demand for digital genome software and products, as seen in initiatives like the COVID-19 Genomic Surveillance Regional Network. The integration of artificial intelligence with genomics, as demonstrated by collaborations such as GE Healthcare and SOPHiA GENETICS, is expected to revolutionize cancer care and clinical research. Despite challenges like high capital expenditure and a shortage of skilled professionals, the market is supported by ongoing research and development activities, particularly in sequence analysis, which is anticipated to hold a significant market share.

North America is expected to lead the digital genome market, bolstered by advanced healthcare infrastructure, increased government investment in research, and a rising incidence of chronic diseases. The region's dominance is further reinforced by the presence of major industry players. The competitive landscape is marked by strategic initiatives such as partnerships, mergers, and new product launches, with key players like bioMérieux, Agilent Technologies, and Inscripta, Inc. making significant contributions. Innovations such as the Onyx platform for genome-scale engineering and cost-effective solutions for whole genome sequencing are set to drive market expansion. As the market continues to evolve, these developments are expected to facilitate significant growth over the forecast period.

Explore More

Global Digital Genome Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increasing Technological Advancements, and Research and Development Pertaining to Digital Genome

      2. 1.2.2 Growing Adoption of Personalized Medicine

      3. 1.2.3 Constantly Evolving Disease Patterns

    3. 1.3 Market Restraints

      1. 1.3.1 High Capital Expenditure

      2. 1.3.2 Lack of Skilled Workforce

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 By Product

      1. 2.1.1 Sequencing and Analyzer Instruments

      2. 2.1.2 DNA/RNA Analysis Kits

      3. 2.1.3 Sequencing Chips

      4. 2.1.4 Sequencing and Analysis Software

      5. 2.1.5 Sample Preparation Instruments

    2. 2.2 By Application

      1. 2.2.1 Clinical

        1. 2.2.1.1 Reproductive Health

        2. 2.2.1.2 Oncology

        3. 2.2.1.3 Others

      2. 2.2.2 Forensics

      3. 2.2.3 Drug Discovery and Development

      4. 2.2.4 Other Applications

    3. 2.3 By End User

      1. 2.3.1 Hospitals

      2. 2.3.2 Diagnostic Centers and Forensic Labs

      3. 2.3.3 Research Institutes

      4. 2.3.4 Other End Users

    4. 2.4 Geography

      1. 2.4.1 North America

        1. 2.4.1.1 United States

        2. 2.4.1.2 Canada

        3. 2.4.1.3 Mexico

      2. 2.4.2 Europe

        1. 2.4.2.1 Germany

        2. 2.4.2.2 United Kingdom

        3. 2.4.2.3 France

        4. 2.4.2.4 Italy

        5. 2.4.2.5 Spain

        6. 2.4.2.6 Rest of Europe

      3. 2.4.3 Asia-Pacific

        1. 2.4.3.1 China

        2. 2.4.3.2 Japan

        3. 2.4.3.3 India

        4. 2.4.3.4 Australia

        5. 2.4.3.5 South Korea

        6. 2.4.3.6 Rest of Asia-Pacific

      4. 2.4.4 Middle-East and Africa

        1. 2.4.4.1 GCC

        2. 2.4.4.2 South Africa

        3. 2.4.4.3 Rest of Middle-East and Africa

      5. 2.4.5 South America

        1. 2.4.5.1 Brazil

        2. 2.4.5.2 Argentina

        3. 2.4.5.3 Rest of South America

Global Digital Genome Market Size FAQs

The Global Digital Genome Market size is expected to reach USD 30.68 billion in 2024 and grow at a CAGR of 13.46% to reach USD 57.68 billion by 2029.

In 2024, the Global Digital Genome Market size is expected to reach USD 30.68 billion.

Digital Genome Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)